AP 1531Alternative Names: BGC-20-1531; PGN-1531
Latest Information Update: 24 Feb 2016
At a glance
- Originator Asterand plc
- Developer BTG
- Class Antimigraines
- Mechanism of Action Prostaglandin E4 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Migraine